How I Rate AstraZeneca Plc As A ‘Buy And Forget’ Share

Is AstraZeneca plc (LON: AZN) a good share to buy and forget for the long term?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m analysing some of the most popular companies in the FTSE 100 to establish if they are attractive long-term buy and forget investments.

Today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US)

What is the sustainable competitive advantage?

At the end of 2012, AstraZeneca was one of the largest pharmaceutical companies in the world, employing over 50,000 people worldwide. Furthermore, AstraZeneca’s Crestor treatment is the world’s eighth bestselling drug, with sales of around $6.3bn.

Indeed, due to its size, AstraZeneca has a certain dominance over the biotechnology market, as many smaller competitors cannot compete with the firm’s financial power and research capabilities.  

Additionally, as AstraZeneca has exclusive production rights for its own treatments, the company can set prices, giving itself a wide profit margin. In particular, even after the loss of some exclusive manufacturing rights last year (which caused a 15% drop in revenue), AstraZeneca’s net profit margin still came in at 22%.

Having said that, AstraZeneca is facing fierce competition from generic producers, which are now manufacturing cheaper versions of some key drugs, after the company’s exclusive manufacturing rights expired last year.

Nonetheless, AstraZeneca’s size and global exposure mean that the company is able to stay ahead of the game, as the firm’s brand attracts talented personal.

Moreover, many larger pharmaceutical companies are now forming research partnerships, in an attempt to offset the stream of patent expirations that are affecting the industry.

Company’s long-term outlook?

With the spectre of disease always present, the demand for AstraZeneca’s products will remain constant, or even grow over the long term, as long as the company can produce treatments that are effective.

It appears that AstraZeneca is well placed to do this. Indeed, the firm has 84 new treatments under development, 13 of which are in the final stages of testing.

Furthermore, AstraZeneca has a strong balance sheet with net debt of only $2bn — a debt to asset ratio of 4%, giving the company plenty of room to acquire smaller competitors as well as new treatments for its pipeline.

Foolish summary

Overall, there will always be a strong demand for AstraZeneca’s products and the company has plenty of treatments under development that will allow it to stay ahead of the game. Additionally, with an almost debt free balance sheet, the company has plenty of room to spend for future growth.

So overall, I rate AstraZeneca as a very good share to buy and forget.

More FTSE opportunities

As well as AstraZeneca, I am also positive on the five FTSE shares highlighted within this exclusive wealth report.

Indeed, all five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for the report — it’s free.

In the meantime, please stay tuned for my next FTSE 100 verdict

> Rupert does not own any share mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

British Isles on nautical map
Investing Articles

Is now a good time to buy in UK stocks?

Retail investors and fund managers are moving away from UK stocks, but there are positive economic signs. Is this an…

Read more »

Dividend Shares

Why hasn’t the Lloyds share price hit £1 yet?

After nearing 75p in early March, the Lloyds share price slumped before bouncing back. What's keeping it from hitting the…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 10 years ago is now worth…

Rolls-Royce shares are tipped to surge and top 800p once again during the next 12 months. Can the FTSE 100…

Read more »

Investing Articles

The FTSE’s down 8% from its highs. Is now a good time to invest in UK shares?

A lot of FTSE shares have taken a hit this year due to economic uncertainty. Is there an opportunity here…

Read more »

Investing Articles

5 lessons from the latest stock-market crash

In a sudden, sharp shock, the US stock market lost over 21% in mere weeks. Though it has rebounded, here…

Read more »

Investing Articles

2 FTSE 250 dividend growth stocks I’ve been buying after recent falls

These FTSE 250 stocks offer tempting income and growth potential, says our writer, who's recently added both to his portfolio.

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

How Trump’s tariffs are re-writing the ISA ‘rule book’

I think a well-balanced ISA should contain a combination of growth and defensive stocks. But recent events are making this…

Read more »

Investing Articles

£10,000 invested in Taylor Wimpey shares 10 years ago is now worth…

Taylor Wimpey's shares have fallen almost a quarter over the past decade. But Royston Wild thinks they may be about…

Read more »